Korean J Med.
2005 Jun;68(6):672-677.
Docetaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer
- Affiliations
-
- 1Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea. jkk21c@knu.ac.kr
- 2Department of General Surgery, Kyungpook National University School of Medicine, Daegu, Korea.
Abstract
-
BACKGROUND: We evaluated the efficacy and toxicity of docetaxel plus cisplatin combination as first-line chemotherapy for advanced gastric cancer.
METHODS
Patients with metastatic or recurrent gastric adenocarcinoma, performance score
Thirty-six patients were enrolled in this study. The overall response rate was 44.4% (95% confidence interval; 27.4~61.5%) and median time to progression was 164 days (95% confidence interval; 78~249 days). The median overall survival of all enrolled patients was 287 days (95% confidence interval: 162~412 days). Grade 3/4 neutropenia was occurred in 7 patients (19.4%) and febrile neutropenia was observed in 6 patients (16.7%).
CONCLUSION
Docetaxel plus cisplatin combination as first-line chemotherapy in patients with advanced gastric cancer was effective and tolerable.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Combination chemotherapy with docetaxel and cisplatin as first-line treatment in advanced gastric cancer: is it a new effective chemotherapy?
- Curative Resection of Inoperable, Locally Advanced Gastric Cancer after Neoadjuvant Chemotherapy with Taxotere and Cisplatin
- Chemotherapy of Advanced Gastric Cancer
- Efficacy and safety of combination chemotherapy with docetaxel and cisplatin as a first-line treatment for advanced gastric cancer
- A New Option for Advanced Gastric Cancer: Docetaxel and Novel Oral Fluoropyrimidine Combination Chemotherapy
